Basal cell carcinoma is the most common skin cancer worldwide. It rarely spreads to distant parts of the body, but it can ...
Veteran hockey and soccer reporter Julie Stewart-Binks revealed she has been absent from live TV as she recovers from skin ...
Regeneron presented new clinical data at ESMO 2026 on Libtayo use in high-risk CSCC and cancer-associated thrombosis.
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell ...